MAPT and Alzheimer disease: The latest development of molecular probes targeting tau made it possible to image tau deposition with PET in vivo non-invasively and dynamically, which suggested a reliable method to characterize AD (Villemagne et al., 2014; Baghel et al., 2019; Teng et al., 2019; Zhao et al., 2019; Chételat et al., 2020; Cho et al., 2020).